iSpecimen (NASDAQ: ISPC) slashes biospecimen shipping times by up to 85%

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

iSpecimen Inc. filed an 8-K to share an operational update on its biospecimen logistics. The company has implemented a streamlined shipping model that sends human biospecimens directly from supplier sites to customers, avoiding prior central-hub routing that often added 7–14 days to delivery times.

Under the new approach, domestic shipments can arrive in as little as 1–2 days, a reduction of about 70–85% in transit time, while using fewer shipment handoffs to lower overall shipping costs. Internationally, iSpecimen has strengthened partnerships across Europe and Eastern Europe to expand access to rare biospecimens and support more consistent, timely deliveries.

The model is supported by enhanced training and operational alignment across the company’s global supplier network. Since implementation earlier in the year, customer feedback has reportedly been positive, with users citing faster, more reliable deliveries and improved overall experience.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Domestic transit time reduction: 70–85% reduction New domestic delivery window: 1–2 days Prior transit delay: 7–14 days

3 metrics

Domestic transit time reduction 70–85% reduction Estimated improvement from new direct shipping model

New domestic delivery window 1–2 days Domestic biospecimen shipments under updated approach

Prior transit delay 7–14 days Additional time from routing through central hub

Key Terms

Regulation FD Disclosure, forward-looking statements, human biospecimens, central hub processing, +1 more

5 terms

Regulation FD Disclosure regulatory

"Item 7.01 Regulation FD Disclosure. On April 9, 2026, iSpecimen Inc..."

forward-looking statements regulatory

"This press release may contain forward-looking statements within the meaning of Section 27A..."

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

human biospecimens financial

"iSpecimen, an online marketplace for human biospecimens, has implemented a streamlined shipping model..."

central hub processing technical

"By reducing reliance on centralized hub processing, the new model simplifies logistics..."

supplier network financial

"The updated model is supported by enhanced training and operational alignment across iSpecimen’s growing global supplier network."

Understanding 8-K Material Events →

04/10/2026 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 9, 2026

iSpecimen Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40501		27-0480143
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

8 Cabot Road, Suite 1800
Woburn, MA 01801

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: (781) 301-6700

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ISPC		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On April 9, 2026, iSpecimen Inc (the “Company”) issued a press release: “iSpecimen Achieves 85% Reduction in Human Biospecimen Shipping Time”. A copy of the press release is attached hereto as Exhibit 99.1.

The information under Item 7.01 of this Current Report on Form 8-K and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release dated April 9, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 10, 2026

iSPECIMEN INC.

By:	/s/ Katharyn Field
	Name:	Katharyn Field
	Title:	Chief Executive Officer

Exhibit 99.1

FOR IMMEDIATE RELEASE

iSpecimen achieves 85% Reduction in Human Biospecimen Shipping Time

Woburn, MA — April 9, 2026 — iSpecimen, an online marketplace for human biospecimens, has implemented a streamlined shipping model that enables direct shipment of biospecimens from supplier sites to customers, both domestically and internationally.

By reducing reliance on centralized hub processing, the new model simplifies logistics and eliminates multi-step routing. Previously, shipments often required routing through a central hub, which could add 7–14 days to transit times. Under the updated approach, domestic shipments can now be delivered in as little as 1–2 days, reducing transit times by approximately 70–85% while also lowering overall shipping costs through fewer shipment handoffs. The updated model is supported by enhanced training and operational alignment across iSpecimen’s growing global supplier network.

For international shipments, iSpecimen has strengthened partnerships with key sourcing organizations across Europe and Eastern Europe, expanding access to rare and hard-to-source biospecimens. Combined with the direct-to-customer shipping model, this expanded network supports broader research requests with improved consistency and turnaround times. The company continues to maintain reliable international shipping operations, ensuring continuity of supply for time-sensitive specimens.

Since its implementation earlier this year, customer feedback has been consistently positive, highlighting improvements in delivery speed, reliability, and overall experience.

“In addition to our AI agent, streamlining shipments is an example of the team’s operational flexibility and expertise. We are pleased with improved timelines all around” commented Katie Field, CEO of iSpecimen. She continued, “Since this process improvement customers have been pleased too, for example one was ‘impressed with the quality and care taken…in the careful sourcing and handling of the research materials.’ We are proud that our customers use rare materials that we source to advance scientific research.”

About iSpecimen

iSpecimen is a technology-driven marketplace that connects life science researchers with a global network of biospecimen suppliers. The Company’s platform simplifies and accelerates access to human biological samples, enabling researchers to find the specimens they need to advance medical science and improve patient outcomes.

Forward Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” “believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties, including risks related to the development, performance, and adoption, and regulatory environment applicable to artificial intelligence technologies. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company’s filings with the SEC, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

For more information, visit www.ispecimen.com

Media Contact

info@ispecimen.com

Source: View Original Filing on SEC EDGAR

FAQ

What did iSpecimen (ISPC) announce in its latest 8-K filing?

iSpecimen reported a new shipping model that sends biospecimens directly from suppliers to customers. This replaces central-hub routing and significantly shortens transit times, aiming to improve delivery speed, reliability, and customer experience for both domestic and international research shipments.

How much has iSpecimen (ISPC) reduced biospecimen shipping times?

iSpecimen states that domestic transit times have been reduced by approximately 70–85%. Shipments that previously took significantly longer due to central-hub routing can now be delivered in as little as 1–2 days, helping researchers receive time-sensitive biospecimens much more quickly.

How does iSpecimen’s new shipping model work for biospecimens?

The company now supports direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. This streamlined approach reduces multi-step routing through a central hub, cutting transit times and shipment handoffs, which can also help lower overall shipping-related costs.

What improvements has iSpecimen (ISPC) made for international biospecimen shipments?

iSpecimen has strengthened partnerships with sourcing organizations across Europe and Eastern Europe. Combined with direct-to-customer shipping, this broader network is intended to support access to rare biospecimens and provide more consistent turnaround times for international research projects.

How have customers responded to iSpecimen’s updated shipping process?

According to the company, customer feedback has been consistently positive since the new model was implemented earlier this year. Clients highlighted faster delivery, improved reliability, and better overall experience, including satisfaction with the care taken in sourcing and handling research materials.

Does iSpecimen mention cost effects from the new shipping model?

The company notes that the streamlined approach lowers overall shipping costs by reducing shipment handoffs. While no specific dollar amounts are provided, fewer routing steps and faster transit times are expected to make logistics more efficient for delivering human biospecimens.

Filing Exhibits & Attachments

4 documents

Press Releases

EX-99.1 PRESS RELEASE DATED APRIL 9, 2026 7.8 KB